# Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Source: https://onco.cc/key-papers/paper-roar-ann-oncol-2022-update/  
OnCo record `paper-roar-ann-oncol-2022-update` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Later report from the ROAR trial registered as NCT02034110, in Annals of Oncology (2022); its title describes an updated or longer-term analysis.

## Summary

Background: Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis of 23 response-assessable patients in the ATC cohort of the phase II Rare Oncology Agnostic Research (ROAR) basket study. We report an updated analysis describing the efficacy and safety of dabrafenib plus trametinib in the full ROAR ATC cohort of 36 patients with ∼4 years of additional study follow-up.

Patients and methods: ROAR (NCT02034110) is an open-label, nonrandomized, phase II basket study evaluating dabrafenib plus trametinib in BRAF V600E-mutant rare cancers. The ATC cohort comprised 36 patients with unresectable or metastatic ATC who received dabrafenib 150 mg twice daily plus trametinib 2 mg once daily orally until disease progression, unacceptable toxicity, or death. The primary endpoint was investigator-assessed overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoints were duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.

Results: At data cutoff (14 September 2020), median follow-up was 11.1 months (range, 0.9-76.6 months). The investigator-assessed ORR was 56% (95% confidence interval, 38.1% to 72.1%), including three complete responses; the 12-month DOR rate was 50%. Median PFS and OS were 6.7 and 14.5 months, respectively. The respective 12-month PFS and OS rates were 43.2% and 51.7%, and the 24-month OS rate was 31.5%. No new safety signals were identified with additional follow-up, and adverse events were consistent with the established tolerability of dabrafenib plus trametinib.

Conclusions: These updated results confirm the substantial clinical benefit and manageable toxicity of dabrafenib plus trametinib in BRAF V600E-mutant ATC. Dabrafenib plus trametinib notably improved long-term survival and represents a meaningful treatment option for this rare, aggressive cancer.

Indexed on Europe PMC as PubMed record 35026411 (DOI 10.1016/j.annonc.2021.12.014). Its abstract cites the registry id NCT02034110, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Tags: europepmc-ingest
- Journal: Annals of Oncology
- Year: 2022
- DOI: 10.1016/j.annonc.2021.12.014
- Authors: Subbiah V, Kreitman RJ, Wainberg ZA, et al.
- What it means: A second publication from the ROAR trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; Chosen as a later report by words in its title (updated, long-term, final, overall survival or a year count), not by reading the paper.

## Sources

- Ann Oncol 2022: https://doi.org/10.1016/j.annonc.2021.12.014
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35026411/
- Europe PMC: https://europepmc.org/article/MED/35026411
- ClinicalTrials.gov NCT02034110: https://clinicaltrials.gov/study/NCT02034110

## Connected records

- trials: [ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort](https://onco.cc/trials/roar/)
- journals: [Annals of Oncology](https://onco.cc/journals/annals-of-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-roar-ann-oncol-2022-update.json